Outcomes and prognostic factors of myelodysplastic syndrome patients with allogeneic hematopoietic stem cell transplantation

Zi-Xian LIU; Meng-Nan LYU; Qian-Qian WANG; Wei-Hua ZHAI; Ai-Ming PANG; Qiao-Ling MA; Dong-Lin YANG; Yi HE; Rong-Li ZHANG; Yong HUANG; Jia-Lin WEI; Si-Zhou FENG; Er-Lie JIANG; Ming-Zhe HAN.
Chinese Journal of Hematology ; (12): 484-489, 2019.
Artículo en Zh | WPRIM | ID: wpr-1012018

Documentos relacionados

  1. [Outcomes and prognostic factors of myelodysplastic syndrome patients with allogeneic hematopoietic stem cell transplantation].
  2. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation.
  3. Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis.
  4. Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome.
  5. Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102.
  6. Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation.
  7. Donor germ-line variants associate with outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes.
  8. Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes.
  9. Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes.
  10. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors.